By Dean Seal

Shares of Solid Biosciences rose after the company said regulators have granted their fast-track designation to its treatment for Duchenne muscular dystrophy.

The stock was up 16% at $3.98 in early trading. Shares are still down 26% year-to-date.

The life sciences company said Thursday that the U.S. Food and Drug Administration granted the designation for SGT-003, its gene therapy candidate for Duchenne muscular dystrophy.

The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 07, 2023 10:34 ET (15:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Solid Biosciences (NASDAQ:SLDB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Solid Biosciences
Solid Biosciences (NASDAQ:SLDB)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Solid Biosciences